 | • レポートコード：GIR-2104Z10690 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、124ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、PEG化医薬品のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。PEG化医薬品の種類別市場規模（高分子医薬品、小分子医薬品、ナノ粒子）、用途別市場規模（がん、C型肝炎、白血病、重症複合免疫不全症、関節リウマチ、クローン病、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・PEG化医薬品の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Bayer Healthcare、Biogen、BioMarin Pharmaceutical Inc、Coherus BioSciences、Enzon、Horizon Therapeutics、Leadiant Biosciences, Inc.、Merck、Mylan、Novo Nordisk、Pfizer、Roche、Sandoz、Servier Pharmaceuticals LLC、Takeda Pharmaceutical Company Limited ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：高分子医薬品、小分子医薬品、ナノ粒子 ・用途別分析2016年-2026年：がん、C型肝炎、白血病、重症複合免疫不全症、関節リウマチ、クローン病、その他 ・PEG化医薬品の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・PEG化医薬品のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・PEG化医薬品のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・PEG化医薬品の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・PEG化医薬品の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The PEGylated Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global PEGylated Drugs size is estimated to be USD 8020.8 million in 2025 from USD 7206.3 million in 2019, with a change XX% between 2019 and 2020. The global PEGylated Drugs market size is expected to grow at a CAGR of 2.7% for the next five years.
Market segmentation
PEGylated Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles
Market segment by Application, can be divided into
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
Market segment by players, this report covers
AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of PEGylated Drugs
1.2 Classification of PEGylated Drugs by Type
1.2.1 Overview: Global PEGylated Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global PEGylated Drugs Revenue Market Share by Type in 2020
1.2.3 Macromolecular Drugs
1.2.4 Small Molecular Drugs
1.2.5 Nanoparticles
1.3 Global PEGylated Drugs Market by Application
1.3.1 Overview: Global PEGylated Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Cancer
1.3.3 Hepatitis C
1.3.4 Leukemia
1.3.5 Severe Combined Immunodeficiency Disease
1.3.6 Rheumatoid Arthritis
1.3.7 Crohn Disease
1.3.8 Others
1.4 Global PEGylated Drugs Market Size & Forecast
1.5 Global PEGylated Drugs Market Size and Forecast by Region
1.5.1 Global PEGylated Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global PEGylated Drugs Market Size by Region, (2016-2021)
1.5.3 North America PEGylated Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe PEGylated Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific PEGylated Drugs Market Size and Prospect (2016-2026)
1.5.6 South America PEGylated Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa PEGylated Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 PEGylated Drugs Market Drivers
1.6.2 PEGylated Drugs Market Restraints
1.6.3 PEGylated Drugs Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PEGylated Drugs Product and Solutions
2.1.4 AstraZeneca PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Bayer Healthcare
2.2.1 Bayer Healthcare Details
2.2.2 Bayer Healthcare Major Business
2.2.3 Bayer Healthcare PEGylated Drugs Product and Solutions
2.2.4 Bayer Healthcare PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bayer Healthcare Recent Developments and Future Plans
2.3 Biogen
2.3.1 Biogen Details
2.3.2 Biogen Major Business
2.3.3 Biogen PEGylated Drugs Product and Solutions
2.3.4 Biogen PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Biogen Recent Developments and Future Plans
2.4 BioMarin Pharmaceutical Inc
2.4.1 BioMarin Pharmaceutical Inc Details
2.4.2 BioMarin Pharmaceutical Inc Major Business
2.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Product and Solutions
2.4.4 BioMarin Pharmaceutical Inc PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 BioMarin Pharmaceutical Inc Recent Developments and Future Plans
2.5 Coherus BioSciences
2.5.1 Coherus BioSciences Details
2.5.2 Coherus BioSciences Major Business
2.5.3 Coherus BioSciences PEGylated Drugs Product and Solutions
2.5.4 Coherus BioSciences PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Coherus BioSciences Recent Developments and Future Plans
2.6 Enzon
2.6.1 Enzon Details
2.6.2 Enzon Major Business
2.6.3 Enzon PEGylated Drugs Product and Solutions
2.6.4 Enzon PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Enzon Recent Developments and Future Plans
2.7 Horizon Therapeutics
2.7.1 Horizon Therapeutics Details
2.7.2 Horizon Therapeutics Major Business
2.7.3 Horizon Therapeutics PEGylated Drugs Product and Solutions
2.7.4 Horizon Therapeutics PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Horizon Therapeutics Recent Developments and Future Plans
2.8 Leadiant Biosciences, Inc.
2.8.1 Leadiant Biosciences, Inc. Details
2.8.2 Leadiant Biosciences, Inc. Major Business
2.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Product and Solutions
2.8.4 Leadiant Biosciences, Inc. PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Leadiant Biosciences, Inc. Recent Developments and Future Plans
2.9 Merck
2.9.1 Merck Details
2.9.2 Merck Major Business
2.9.3 Merck PEGylated Drugs Product and Solutions
2.9.4 Merck PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Merck Recent Developments and Future Plans
2.10 Mylan
2.10.1 Mylan Details
2.10.2 Mylan Major Business
2.10.3 Mylan PEGylated Drugs Product and Solutions
2.10.4 Mylan PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Mylan Recent Developments and Future Plans
2.11 Novo Nordisk
2.11.1 Novo Nordisk Details
2.11.2 Novo Nordisk Major Business
2.11.3 Novo Nordisk PEGylated Drugs Product and Solutions
2.11.4 Novo Nordisk PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Novo Nordisk Recent Developments and Future Plans
2.12 Pfizer
2.12.1 Pfizer Details
2.12.2 Pfizer Major Business
2.12.3 Pfizer PEGylated Drugs Product and Solutions
2.12.4 Pfizer PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Pfizer Recent Developments and Future Plans
2.13 Roche
2.13.1 Roche Details
2.13.2 Roche Major Business
2.13.3 Roche PEGylated Drugs Product and Solutions
2.13.4 Roche PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Roche Recent Developments and Future Plans
2.14 Sandoz
2.14.1 Sandoz Details
2.14.2 Sandoz Major Business
2.14.3 Sandoz PEGylated Drugs Product and Solutions
2.14.4 Sandoz PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Sandoz Recent Developments and Future Plans
2.15 Servier Pharmaceuticals LLC
2.15.1 Servier Pharmaceuticals LLC Details
2.15.2 Servier Pharmaceuticals LLC Major Business
2.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Product and Solutions
2.15.4 Servier Pharmaceuticals LLC PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Servier Pharmaceuticals LLC Recent Developments and Future Plans
2.16 Takeda Pharmaceutical Company Limited
2.16.1 Takeda Pharmaceutical Company Limited Details
2.16.2 Takeda Pharmaceutical Company Limited Major Business
2.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Product and Solutions
2.16.4 Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PEGylated Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 PEGylated Drugs Players Market Share
3.2.2 Top 10 PEGylated Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 PEGylated Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global PEGylated Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global PEGylated Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global PEGylated Drugs Revenue Market Share by Application (2016-2021)
5.2 PEGylated Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America PEGylated Drugs Revenue by Type (2016-2026)
6.2 North America PEGylated Drugs Revenue by Application (2016-2026)
6.3 North America PEGylated Drugs Market Size by Country
6.3.1 North America PEGylated Drugs Revenue by Country (2016-2026)
6.3.2 United States PEGylated Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada PEGylated Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico PEGylated Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe PEGylated Drugs Revenue by Type (2016-2026)
7.2 Europe PEGylated Drugs Revenue by Application (2016-2026)
7.3 Europe PEGylated Drugs Market Size by Country
7.3.1 Europe PEGylated Drugs Revenue by Country (2016-2026)
7.3.2 Germany PEGylated Drugs Market Size and Forecast (2016-2026)
7.3.3 France PEGylated Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom PEGylated Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia PEGylated Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy PEGylated Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PEGylated Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific PEGylated Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific PEGylated Drugs Market Size by Region
8.3.1 Asia-Pacific PEGylated Drugs Revenue by Region (2016-2026)
8.3.2 China PEGylated Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan PEGylated Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea PEGylated Drugs Market Size and Forecast (2016-2026)
8.3.5 India PEGylated Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia PEGylated Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia PEGylated Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America PEGylated Drugs Revenue by Type (2016-2026)
9.2 South America PEGylated Drugs Revenue by Application (2016-2026)
9.3 South America PEGylated Drugs Market Size by Country
9.3.1 South America PEGylated Drugs Revenue by Country (2016-2026)
9.3.2 Brazil PEGylated Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina PEGylated Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PEGylated Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa PEGylated Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa PEGylated Drugs Market Size by Country
10.3.1 Middle East & Africa PEGylated Drugs Revenue by Country (2016-2026)
10.3.2 Turkey PEGylated Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia PEGylated Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE PEGylated Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global PEGylated Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global PEGylated Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market PEGylated Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global PEGylated Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global PEGylated Drugs Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca PEGylated Drugs Product and Solutions
Table 9. AstraZeneca PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bayer Healthcare Corporate Information, Head Office, and Major Competitors
Table 11. Bayer Healthcare Major Business
Table 12. Bayer Healthcare PEGylated Drugs Product and Solutions
Table 13. Bayer Healthcare PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Biogen Corporate Information, Head Office, and Major Competitors
Table 15. Biogen Major Business
Table 16. Biogen PEGylated Drugs Product and Solutions
Table 17. Biogen PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. BioMarin Pharmaceutical Inc Corporate Information, Head Office, and Major Competitors
Table 19. BioMarin Pharmaceutical Inc Major Business
Table 20. BioMarin Pharmaceutical Inc PEGylated Drugs Product and Solutions
Table 21. BioMarin Pharmaceutical Inc PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Coherus BioSciences Corporate Information, Head Office, and Major Competitors
Table 23. Coherus BioSciences Major Business
Table 24. Coherus BioSciences PEGylated Drugs Product and Solutions
Table 25. Coherus BioSciences PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Enzon Corporate Information, Head Office, and Major Competitors
Table 27. Enzon Major Business
Table 28. Enzon PEGylated Drugs Product and Solutions
Table 29. Enzon PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Horizon Therapeutics Corporate Information, Head Office, and Major Competitors
Table 31. Horizon Therapeutics Major Business
Table 32. Horizon Therapeutics PEGylated Drugs Product and Solutions
Table 33. Horizon Therapeutics PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Leadiant Biosciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Leadiant Biosciences, Inc. Major Business
Table 36. Leadiant Biosciences, Inc. PEGylated Drugs Product and Solutions
Table 37. Leadiant Biosciences, Inc. PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Merck Corporate Information, Head Office, and Major Competitors
Table 39. Merck Major Business
Table 40. Merck PEGylated Drugs Product and Solutions
Table 41. Merck PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Mylan Corporate Information, Head Office, and Major Competitors
Table 43. Mylan Major Business
Table 44. Mylan PEGylated Drugs Product and Solutions
Table 45. Mylan PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 47. Novo Nordisk Major Business
Table 48. Novo Nordisk PEGylated Drugs Product and Solutions
Table 49. Novo Nordisk PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Pfizer Corporate Information, Head Office, and Major Competitors
Table 51. Pfizer Major Business
Table 52. Pfizer PEGylated Drugs Product and Solutions
Table 53. Pfizer PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Roche Corporate Information, Head Office, and Major Competitors
Table 55. Roche Major Business
Table 56. Roche PEGylated Drugs Product and Solutions
Table 57. Roche PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Sandoz Corporate Information, Head Office, and Major Competitors
Table 59. Sandoz Major Business
Table 60. Sandoz PEGylated Drugs Product and Solutions
Table 61. Sandoz PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Servier Pharmaceuticals LLC Corporate Information, Head Office, and Major Competitors
Table 63. Servier Pharmaceuticals LLC Major Business
Table 64. Servier Pharmaceuticals LLC PEGylated Drugs Product and Solutions
Table 65. Servier Pharmaceuticals LLC PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Takeda Pharmaceutical Company Limited Corporate Information, Head Office, and Major Competitors
Table 67. Takeda Pharmaceutical Company Limited Major Business
Table 68. Takeda Pharmaceutical Company Limited PEGylated Drugs Product and Solutions
Table 69. Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Global PEGylated Drugs Revenue (USD Million) by Players (2019-2021)
Table 71. Global PEGylated Drugs Revenue Share by Players (2019-2021)
Table 72. Breakdown of PEGylated Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 73. PEGylated Drugs Players Head Office, Products and Services Provided
Table 74. PEGylated Drugs Mergers & Acquisitions in the Past Five Years
Table 75. PEGylated Drugs New Entrants and Expansion Plans
Table 76. Global PEGylated Drugs Revenue (USD Million) by Type (2016-2021)
Table 77. Global PEGylated Drugs Revenue Share by Type (2016-2021)
Table 78. Global PEGylated Drugs Revenue Forecast by Type (2021-2026)
Table 79. Global PEGylated Drugs Revenue by Application (2016-2021)
Table 80. Global PEGylated Drugs Revenue Forecast by Application (2021-2026)
Table 81. North America PEGylated Drugs Revenue by Type (2016-2021) & (USD Million)
Table 82. North America PEGylated Drugs Revenue by Type (2021-2026) & (USD Million)
Table 83. North America PEGylated Drugs Revenue by Application (2016-2021) & (USD Million)
Table 84. North America PEGylated Drugs Revenue by Application (2021-2026) & (USD Million)
Table 85. North America PEGylated Drugs Revenue by Country (2016-2021) & (USD Million)
Table 86. North America PEGylated Drugs Revenue by Country (2021-2026) & (USD Million)
Table 87. Europe PEGylated Drugs Revenue by Type (2016-2021) & (USD Million)
Table 88. Europe PEGylated Drugs Revenue by Type (2021-2026) & (USD Million)
Table 89. Europe PEGylated Drugs Revenue by Application (2016-2021) & (USD Million)
Table 90. Europe PEGylated Drugs Revenue by Application (2021-2026) & (USD Million)
Table 91. Europe PEGylated Drugs Revenue by Country (2016-2021) & (USD Million)
Table 92. Europe PEGylated Drugs Revenue by Country (2021-2026) & (USD Million)
Table 93. Asia-Pacific PEGylated Drugs Revenue by Type (2016-2021) & (USD Million)
Table 94. Asia-Pacific PEGylated Drugs Revenue by Type (2021-2026) & (USD Million)
Table 95. Asia-Pacific PEGylated Drugs Revenue by Application (2016-2021) & (USD Million)
Table 96. Asia-Pacific PEGylated Drugs Revenue by Application (2021-2026) & (USD Million)
Table 97. Asia-Pacific PEGylated Drugs Revenue by Region (2016-2021) & (USD Million)
Table 98. Asia-Pacific PEGylated Drugs Revenue by Region (2021-2026) & (USD Million)
Table 99. South America PEGylated Drugs Revenue by Type (2016-2021) & (USD Million)
Table 100. South America PEGylated Drugs Revenue by Type (2021-2026) & (USD Million)
Table 101. South America PEGylated Drugs Revenue by Application (2016-2021) & (USD Million)
Table 102. South America PEGylated Drugs Revenue by Application (2021-2026) & (USD Million)
Table 103. South America PEGylated Drugs Revenue by Country (2016-2021) & (USD Million)
Table 104. South America PEGylated Drugs Revenue by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa PEGylated Drugs Revenue by Type (2016-2021) & (USD Million)
Table 106. Middle East & Africa PEGylated Drugs Revenue by Type (2021-2026) & (USD Million)
Table 107. Middle East & Africa PEGylated Drugs Revenue by Application (2016-2021) & (USD Million)
Table 108. Middle East & Africa PEGylated Drugs Revenue by Application (2021-2026) & (USD Million)
Table 109. Middle East & Africa PEGylated Drugs Revenue by Country (2016-2021) & (USD Million)
Table 110. Middle East & Africa PEGylated Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. PEGylated Drugs Picture
Figure 2. Global PEGylated Drugs Revenue Market Share by Type in 2020
Figure 3. Macromolecular Drugs
Figure 4. Small Molecular Drugs
Figure 5. Nanoparticles
Figure 6. PEGylated Drugs Revenue Market Share by Application in 2020
Figure 7. Cancer Picture
Figure 8. Hepatitis C Picture
Figure 9. Leukemia Picture
Figure 10. Severe Combined Immunodeficiency Disease Picture
Figure 11. Rheumatoid Arthritis Picture
Figure 12. Crohn Disease Picture
Figure 13. Others Picture
Figure 14. Global PEGylated Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global PEGylated Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global PEGylated Drugs Revenue Market Share by Region (2016-2026)
Figure 17. Global PEGylated Drugs Revenue Market Share by Region in 2020
Figure 18. North America PEGylated Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe PEGylated Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific PEGylated Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America PEGylated Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. PEGylated Drugs Market Drivers
Figure 23. PEGylated Drugs Market Restraints
Figure 24. PEGylated Drugs Market Trends
Figure 25. AstraZeneca Recent Developments and Future Plans
Figure 26. Bayer Healthcare Recent Developments and Future Plans
Figure 27. Biogen Recent Developments and Future Plans
Figure 28. BioMarin Pharmaceutical Inc Recent Developments and Future Plans
Figure 29. Coherus BioSciences Recent Developments and Future Plans
Figure 30. Enzon Recent Developments and Future Plans
Figure 31. Horizon Therapeutics Recent Developments and Future Plans
Figure 32. Leadiant Biosciences, Inc. Recent Developments and Future Plans
Figure 33. Merck Recent Developments and Future Plans
Figure 34. Mylan Recent Developments and Future Plans
Figure 35. Novo Nordisk Recent Developments and Future Plans
Figure 36. Pfizer Recent Developments and Future Plans
Figure 37. Roche Recent Developments and Future Plans
Figure 38. Sandoz Recent Developments and Future Plans
Figure 39. Servier Pharmaceuticals LLC Recent Developments and Future Plans
Figure 40. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Figure 42. Global PEGylated Drugs Revenue Share by Players in 2020
Figure 43. PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 44. Global Top 3 Players PEGylated Drugs Revenue Market Share in 2020
Figure 45. Global Top 10 Players PEGylated Drugs Revenue Market Share in 2020
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 47. Global PEGylated Drugs Revenue Share by Type in 2020
Figure 48. Global PEGylated Drugs Market Share Forecast by Type (2021-2026)
Figure 49. Global PEGylated Drugs Revenue Share by Application in 2020
Figure 50. Global PEGylated Drugs Market Share Forecast by Application (2021-2026)
Figure 51. North America PEGylated Drugs Sales Market Share by Type (2016-2026)
Figure 52. North America PEGylated Drugs Sales Market Share by Application (2016-2026)
Figure 53. North America PEGylated Drugs Revenue Market Share by Country (2016-2026)
Figure 54. United States PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Canada PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Mexico PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Europe PEGylated Drugs Sales Market Share by Type (2016-2026)
Figure 58. Europe PEGylated Drugs Sales Market Share by Application (2016-2026)
Figure 59. Europe PEGylated Drugs Revenue Market Share by Country (2016-2026)
Figure 60. Germany PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. France PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. United Kingdom PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Russia PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Italy PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Asia-Pacific PEGylated Drugs Sales Market Share by Type (2016-2026)
Figure 66. Asia-Pacific PEGylated Drugs Sales Market Share by Application (2016-2026)
Figure 67. Asia-Pacific PEGylated Drugs Revenue Market Share by Region (2016-2026)
Figure 68. China PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Japan PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South Korea PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. India PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Southeast Asia PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Australia PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. South America PEGylated Drugs Sales Market Share by Type (2016-2026)
Figure 75. South America PEGylated Drugs Sales Market Share by Application (2016-2026)
Figure 76. South America PEGylated Drugs Revenue Market Share by Country (2016-2026)
Figure 77. Brazil PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Argentina PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Middle East and Africa PEGylated Drugs Sales Market Share by Type (2016-2026)
Figure 80. Middle East and Africa PEGylated Drugs Sales Market Share by Application (2016-2026)
Figure 81. Middle East and Africa PEGylated Drugs Revenue Market Share by Country (2016-2026)
Figure 82. Turkey PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Saudi Arabia PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. UAE PEGylated Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source
世界のPEG化薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global PEGylated Drugs Market The global PEGylated Drugs market size is projected to reach US$ 8536.5 million by 2026, from US$ 7003.6 million in 2019, at a CAGR of 2.8% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report ma…- 世界のPEG化タンパク質治療薬市場規模・現状・予測（2021年-2027年） PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth …
- 世界のエルウィニアL-アスパラギナーゼ薬市場 2021：企業別、地域別、種類・用途別 The Erwinia L-Asparaginase Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade re…
- 世界のイロプロスト薬市場規模・現状・予測（2021年-2027年） Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues. North America is estimated to have a major share in the global market with 75%. Market Analysis…
- 世界の骨髄異形成症候群（MDS）治療薬市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …